<qa>  What is the major objective of NA treatment regimes according to current guidelines?HBeAg loss or seroconversion In HBeAg positive patients, HBeAg loss or seroconversion is the major objective of NA treatment regimes according to current guidelines. HBeAg loss or seroconversion is usually associated with sustained remission and a very low risk for the development of cirrhosis and hepatocellular carcinoma. 11-13 PEG-IFN induced HBeAg seroconversion was shown to be sustained in 70 after a 3 year follow up. 14 There are some contradictory results concerning NA induced durability of HBeAg loss or seroconversion. First reports on lamuvidine induced HBeAg loss or seroconversion were rather promising.15-17 However, more recent and also larger studies report much higher relapse rates and predictors of sustainability were proposed. 18-21 The registration trial of entecavir showed a 82 durability after 24 weeks without consolidation therapy.6 Recently we showed that the durability of HBeAg seroconversion was very poor with 42, 58 and 74 seroreversion respectively 1,2 and 3 years after seroconversion on different NA treatment regimes. However, only a minority of these patients was treated with the newer and more potent NA. 22 